MedTrace Logo

Magnetic Resonance-guided Adaptive Stereotactic Body Radiotherapy for Hepatic Metastases

NCT05027711 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2026-03-10

No results posted yet for this study

Summary

Stereotactic body radiotherapy (SBRT) is an established local treatment method for patients with hepatic oligometastases. Liver metastases often occur in close proximity to radiosensitive organs at risk (OARs). This limits the possibility to apply sufficiently high doses needed for optimal local control. MR-guided radiotherapy (MRgRT) is expected to hold potential to improve hepatic SBRT by offering superior soft-tissue contrast for enhanced target identification as well as the benefit of daily real-time adaptive treatment. The MAESTRO trial therefore aims to assess the potential advantages of adaptive, gated MR-guided SBRT (MRgSBRT) compared to conventional SBRT at a standard linac using an ITV (internal target volume) approach (ITV-SBRT).

Conditions

  • Hepatic Metastasis

Interventions

RADIATION

ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)

ITV (Internal target volume)-based Stereotactic Body Radiotherapy (ITV-SBRT)

RADIATION

MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)

MRgSBRT (Magnetic Resonance-guided Stereotactic Body Radiotherapy)

Sponsors & Collaborators

  • University Hospital Heidelberg

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-12
Primary Completion
2029-01-31
Completion
2030-01-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05027711 on ClinicalTrials.gov